Abstract: A transistor includes an insulating layer, a source region, a drain region, a channel layer, a ferroelectric layer, and a gate electrode. The source region and the drain region are respectively disposed on and in physical contact with two opposite sidewalls of the insulating layer. A thickness of the source region, a thickness of the drain region, and a thickness of the insulating layer are substantially the same. The channel layer is disposed on the insulating layer, the source region, and the drain region. The ferroelectric layer is disposed over the channel layer. The gate electrode is disposed on the ferroelectric layer.

Abstract: A method for identifying a potential biomarker for determining the probability of the success of embryo implantation by assaying a methylation profile of cervical secretions.

Abstract: Disclosed herein are various methods for assessing the presence of gynecologic neoplasm or the malignancy of the gynecologic neoplasm, based on the hypermethylation of one or more marker genes.

Abstract: A sampling device for vaginal specimens is revealed. The sampling device for vaginal specimens includes a tubular unit whose one end is disposed with a sampling unit, and at least one hole arranged on side walls of the same end of the tubular unit. The other end of the tubular unit is disposed with a saclike body or is inserted with an injection unit so as to send solution through the tubular unit to the hole for flushing vagina. By the sampling unit, a flushed vaginal specimen is collected. Thus the collection procedures of the specimen are easy and convenient to be performed and users have no uncomfortable feelings due to the lubricant solution.

Abstract: The present invention uses methylomic analysis and discovers DNA methylation biomarkers for prediction of ovarian cancer prognosis and detection of malignant ovarian cancer. In addition to being independent prognostic factors for patients with current treatment protocols, these DNA methylations are important biomarkers for individualized medicine for future chemotherapy (especially the demethylation agents or other epigenetic drugs).

Abstract: The present invention discloses compounds for the treatment of cancer and its application. These compounds comprises one of the following compound: Ammonium pyrrolidinedithiocarbamate Bay 11-7085 BIO Brefeldin A (+)-Butaclamol Calcimycin Calmidazoliur chloride Chelerythrine chloride CK2 Inhibitor 2 CGP-74514A hydrochloride CGS-12066A meleate Dequalinium dichloride Dihydroouabain Diphenyleneiodonium chloride Emetine dihydrochloride hydrate GR 127935 hydrochloride Nifedipine 6-Nitroso-1,2-benzopyrone Palmitoyl-DL-Carnitine chloride Parthenolide PD 169316 1,10-Phenanthroline monohydrate 4-Phenyl-3-furoxancarbonitrile Prazosin hydrochloride Protoporphyrin IX disodium Quinacrine dihydrochloride Quabain Retinoic acid p-hydroxyanilide Rottlerin Sanguinarine chloride Tetraethylthium disulfide and SU 9516.

Abstract: A method for screening cancer comprises the following steps: (1) providing a test specimen; (2) detecting the methylation rate of the CpG sequence in at least one target gene of the test specimen, wherein the target genes is consisted of PTPRR, ZNF582, PDE8B and DBC1; and (3) determining whether there is cancer or cancerous pathological change in the specimen based on the methylation rate in the target gene.

Abstract: A sampling device for vaginal specimens is revealed. The sampling device for vaginal specimens includes a tubular unit whose one end is disposed with a sampling unit, and at least one hole arranged on side walls of the same end of the tubular unit. The other end of the tubular unit is disposed with a saclike body or is inserted with an injection unit so as to send solution through the tubular unit to the hole for flushing vagina. By the sampling unit, a flushed vaginal specimen is collected. Thus the collection procedures of the specimen are easy and convenient to be performed and users have no uncomfortable feelings due to the lubricant solution.

Abstract: A method for screening cancer comprises the following steps: (1) providing a test specimen; (2) detecting the methylation rate of the CpG sequence in at least one target gene of the test specimen, wherein the target genes is consisted of PTPRR, ZNF582, PDE8B and DBC1; and (3) determining whether there is cancer or cancerous pathological change in the specimen based on the methylation rate in the target gene.

Abstract: A method for screening cancer comprises the following steps: (1) providing a test specimen; (2) detecting the methylation state of the CpG sequence in at least one target gene within the genomic DNA of the test specimen, wherein the target genes is consisted of SOX1, PAX1, LMX1A, NKX6-1, WT1 and ONECUT1; and (3) determining whether there is cancer or cancerous pathological change in the specimen based on the presence or absence of the methylation state in the target gene; wherein method for detecting methylation state is methylation-specific PCR (MSP), quantitative methylation-specific PCR (QMSP), bisulfite sequencing (BS), microarrays, mass spectrometer, denaturing high-performance liquid chromatography (DHPLC), and pyrosequencing.

Abstract: A method for screening cancer comprises the following steps: (1) providing a test specimen; (2) detecting the methylation state of the CpG sequence in at least one target gene within the genomic DNA of the test specimen, wherein the target genes is consisted of SOX1, PAX1, LMX1A, NKX6-1, WT1 and ONECUT1; and (3) determining whether there is cancer or cancerous pathological change in the specimen based on the presence or absence of the methylation state in the target gene; wherein method for detecting methylation state is methylation-specific PCR (MSP), quantitative methylation-specific PCR (QMSP), bisulfite sequencing (BS), microarrays, mass spectrometer, denaturing high-performance liquid chromatography (DHPLC), and pyrosequencing.